Multi-precursor NAD+ blends combine NMN or NR with CD38 inhibitors and methylation cofactors for comprehensive NAD+ optimization in a single product. The blends below have published ingredient transparency and human data.

Selection criteria. Multiple NAD+-pathway ingredients (precursor + CD38 inhibitor or sirtuin activator); transparent ingredient panel; >12 months commercial history.

This guide ranks our top picks, explains the methodology, and gives you a clear protocol for getting started.

NAD+ (nicotinamide adenine dinucleotide) is a redox coenzyme present in every cell. It powers mitochondrial ATP production via the electron-transport chain, fuels DNA-repair enzymes (PARPs), and is the obligatory substrate for sirtuins (SIRT1–SIRT7) — the enzyme family that controls gene expression, inflammation, and cellular survival.

NAD+ levels fall by 50% or more between ages 30 and 60. That decline is now considered a leading mechanistic explanation for age-related metabolic dysfunction, mitochondrial fatigue, accumulation of senescent cells, and the loss of muscle, skin, and cognitive resilience seen in aging.